3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Burkitt Lymphoma
5
Prostatic Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Leukemia, Biphenotypic, Acute
2
Hematologic Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostate Cancer Recurrent
1
Philadelphia Chromosome
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Interventions
Cyclophosphamide
26
fludarabine
18
Dexamethasone
17
pembrolizumab
12
Rituximab
11
Etoposide
10
venetoclax
9
pomalidomide
9
Gemcitabine
9
fludarabine phosphate
7
daratumumab
7
Lenalidomide
7
Bortezomib
7
carfilzomib
6
obinutuzumab
5
glofitamab
5
Vincristine
5
Temozolomide
5
Prednisone
5
Nivolumab
5
Immunotherapy, Adoptive
5
Cisplatin
5
Calcium Dobesilate
5
selinexor
4
cemiplimab
4
Doxorubicin
4
Cytarabine
4
Carboplatin
4
zanubrutinib
3
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
Dasatinib
×
90 days
×
Clear all
No trials found.